{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T13:38:17Z","timestamp":1790861897457,"version":"4.1.0"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T00:00:00Z","timestamp":1753142400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T00:00:00Z","timestamp":1753142400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002739","name":"Aarhus Universitets Forskningsfond","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002739","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007696","name":"Oticon Fonden","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007696","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007436","name":"Torben og Alice Frimodts Fond","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007436","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008363","name":"Kr\u00e6ftens Bek\u00e6mpelse","doi-asserted-by":"publisher","award":["R336-A19239"],"award-info":[{"award-number":["R336-A19239"]}],"id":[{"id":"10.13039\/100008363","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008363","name":"Kr\u00e6ftens Bek\u00e6mpelse","doi-asserted-by":"publisher","award":["R147-A10100"],"award-info":[{"award-number":["R147-A10100"]}],"id":[{"id":"10.13039\/100008363","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008363","name":"Kr\u00e6ftens Bek\u00e6mpelse","doi-asserted-by":"publisher","award":["R378-A22231"],"award-info":[{"award-number":["R378-A22231"]}],"id":[{"id":"10.13039\/100008363","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA286069"],"award-info":[{"award-number":["R01CA286069"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA286069"],"award-info":[{"award-number":["R01CA286069"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2025,10,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>The anti-cancer potential of low-dose aspirin in long-term breast cancer (BC) survivors remain unknown. We evaluated the association between low-dose aspirin use and BC recurrence and mortality.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Women \u226540 years diagnosed with stage I-III BC (1996\u20132004) were identified from the Danish Breast Cancer Group (DBCG) database and information on aspirin use from the Danish Prescription Registry. We ascertained recurrences from DBCG and via a validated algorithm. We plotted cumulative incidences of recurrence and mortality, accounting for competing risks. Using Cox regression, we estimated hazard ratios (HRs) and 95% confidence intervals (CI), employing landmark analyses at 5-, 10-, and 15-year post-diagnosis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Among 20,509 BC survivors, 4527 developed recurrence over 232,441 person-years of follow-up. The 20-year cumulative incidence of recurrence was lower in users (17.8%) than nonusers (22.4%), with similar trends among 10-year disease-free survivors (9.9% vs. 12.7%). We observed reduced HRs of recurrence (adjusted HR<jats:sub>5-year<\/jats:sub>\u2009=\u20090.80, (95% CI\u2009=\u20090.66-0.98); HR<jats:sub>10-year<\/jats:sub>\u2009=\u20090.87 (0.73\u20131.05); HR<jats:sub>15-year<\/jats:sub>\u2009=\u20090.82 (0.57\u20131.17) in aspirin users, but increased HRs of all-cause mortality (HR<jats:sub>5-year<\/jats:sub>\u2009=\u20091.08 (0.96\u20131.21); HR<jats:sub>10-year<\/jats:sub>\u2009=\u20091.09 (0.96\u20131.24); HR<jats:sub>15-year<\/jats:sub>\u2009=\u20091.09 (0.80\u20131.31).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>The reduced recurrence risk in aspirin users may indicate potential anti-cancer effects of aspirin, though the increased risk of death suggests influence by confounding by indication and competing risks.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1038\/s41416-025-03112-3","type":"journal-article","created":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T00:26:39Z","timestamp":1753143999000},"page":"865-873","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Association between low-dose aspirin use and breast cancer recurrence: a Danish nationwide cohort study with up to 23 years of follow-up"],"prefix":"10.1038","volume":"133","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4185-1074","authenticated-orcid":false,"given":"Elisabeth","family":"Solmunde","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rikke N.","family":"Pedersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6110-5891","authenticated-orcid":false,"given":"Mette","family":"N\u00f8rgaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lene","family":"Mellemkj\u00e6r","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00f8ren","family":"Friis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8761-714X","authenticated-orcid":false,"given":"Bent","family":"Ejlertsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0440-8727","authenticated-orcid":false,"given":"Thomas P.","family":"Ahern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9738-2284","authenticated-orcid":false,"given":"Deirdre P.","family":"Cronin-Fenton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,22]]},"reference":[{"key":"3112_CR1","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209\u201349.","journal-title":"CA Cancer J Clin"},{"key":"3112_CR2","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1080\/0284186X.2017.1408962","volume":"57","author":"B Ejlertsen","year":"2018","unstructured":"Ejlertsen B, Offersen BV, Overgaard J, Christiansen P, Jensen MB, Kroman N, et al. Forty years of landmark trials undertaken by the Danish Breast Cancer Cooperative Group (DBCG) nationwide or in international collaboration. Acta Oncol. 2018;57:3\u201312.","journal-title":"Acta Oncol"},{"issue":"Suppl 2","key":"3112_CR3","doi-asserted-by":"publisher","first-page":"24","DOI":"10.3109\/0284186X.2015.1128119","volume":"55","author":"MB Jensen","year":"2016","unstructured":"Jensen MB, Ejlertsen B, Mouridsen HT, Christiansen P. Improvements in breast cancer survival between 1995 and 2012 in Denmark: the importance of earlier diagnosis and adjuvant treatment. Acta Oncol. 2016;55(Suppl 2):24\u201335.","journal-title":"Acta Oncol"},{"key":"3112_CR4","unstructured":"NORDCAN. 10-year age-standardised relative survival (%), Females [Internet]. 2024 [cited 2024 Dec 9]. Available from: https:\/\/nordcan.iarc.fr\/en\/dataviz\/survival?mode=cancer&group_populations=0&multiple_cancers=1&key=total&types=3&sexes=2&cancers=180&populations=208&multiple_populations=0&years_available=1943_2023&survival=10&surv_period=5&years=1943_2018&show_map_view_per_prop=0."},{"key":"3112_CR5","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1097\/EDE.0000000000000480","volume":"27","author":"DP Cronin-Fenton","year":"2016","unstructured":"Cronin-Fenton DP, Heide-J\u00f8rgensen U, Ahern TP, Lash TL, Christiansen P, Ejlertsen B, et al. Low-dose aspirin, nonsteroidal anti-inflammatory drugs, selective COX-2 inhibitors and breast cancer recurrence. Epidemiology. 2016;27:586\u201393.","journal-title":"Epidemiology"},{"key":"3112_CR6","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1093\/jnci\/djab202","volume":"114","author":"RN Pedersen","year":"2022","unstructured":"Pedersen RN, Esen B\u00d6, Mellemkj\u00e6r L, Christiansen P, Ejlertsen B, Lash TL, et al. The incidence of breast cancer recurrence 10-32 years after primary diagnosis. J Natl Cancer Inst. 2022;114:391\u20139.","journal-title":"J Natl Cancer Inst"},{"key":"3112_CR7","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1093\/jnci\/djab203","volume":"114","author":"S Negoita","year":"2022","unstructured":"Negoita S, Ramirez-Pena E. Prevention of late recurrence: an increasingly important target for breast cancer research and control. J Natl Cancer Inst. 2022;114:340\u20131.","journal-title":"J Natl Cancer Inst"},{"key":"3112_CR8","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1146\/annurev.biochem.69.1.145","volume":"69","author":"WL Smith","year":"2000","unstructured":"Smith WL, DeWitt DL, Garavito RM. Cyclooxygenases: structural, cellular, and molecular biology. Annu Rev Biochem. 2000;69:145\u201382.","journal-title":"Annu Rev Biochem"},{"key":"3112_CR9","unstructured":"Cantley L. G-protein second messengers: arachidonic acid metabolites. In: Boron WF, Boulpaep EL, editors. Medical physiology. Philadelphia, PA: Elsevier; 2017. p. 62\u20134."},{"key":"3112_CR10","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1007\/s10555-017-9675-z","volume":"36","author":"A Ornelas","year":"2017","unstructured":"Ornelas A, Zacharias-Millward N, Menter DG, Davis JS, Lichtenberger L, Hawke D, et al. Beyond COX-1: the effects of aspirin on platelet biology and potential mechanisms of chemoprevention. Cancer Metastasis Rev. 2017;36:289\u2013303.","journal-title":"Cancer Metastasis Rev"},{"key":"3112_CR11","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1038\/nrc3004","volume":"11","author":"LJ Gay","year":"2011","unstructured":"Gay LJ, Felding-Habermann B. Contribution of platelets to tumour metastasis. Nat Rev Cancer. 2011;11:123\u201334.","journal-title":"Nat Rev Cancer"},{"key":"3112_CR12","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1016\/S0140-6736(09)60243-9","volume":"373","author":"PC Elwood","year":"2009","unstructured":"Elwood PC, Gallagher AM, Duthie GG, Mur LA, Morgan G. Aspirin, salicylates, and cancer. Lancet. 2009;373:1301\u20139.","journal-title":"Lancet"},{"key":"3112_CR13","doi-asserted-by":"publisher","DOI":"10.1186\/bcr1678","volume":"9","author":"LR Howe","year":"2007","unstructured":"Howe LR. Inflammation and breast cancer. Cyclooxygenase\/prostaglandin signaling and breast cancer. Breast Cancer Res. 2007;9:210.","journal-title":"Breast Cancer Res"},{"key":"3112_CR14","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1200\/JCO.2009.22.7918","volume":"28","author":"MD Holmes","year":"2010","unstructured":"Holmes MD, Chen WY, Li L, Hertzmark E, Spiegelman D, Hankinson SE. Aspirin intake and survival after breast cancer. J Clin Oncol. 2010;28:1467\u201372.","journal-title":"J Clin Oncol"},{"key":"3112_CR15","doi-asserted-by":"publisher","first-page":"18563","DOI":"10.1074\/jbc.M010787200","volume":"276","author":"CH Liu","year":"2001","unstructured":"Liu CH, Chang SH, Narko K, Trifan OC, Wu MT, Smith E, et al. Overexpression of cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice. J Biol Chem. 2001;276:18563\u20139.","journal-title":"J Biol Chem"},{"key":"3112_CR16","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1158\/1055-9965.EPI-11-1012","volume":"21","author":"Y Li","year":"2012","unstructured":"Li Y, Brasky TM, Nie J, Ambrosone CB, McCann SE, Shields PG, et al. Use of nonsteroidal anti-inflammatory drugs and survival following breast cancer diagnosis. Cancer Epidemiol Biomark Prev. 2012;21:239\u201342.","journal-title":"Cancer Epidemiol Biomark Prev"},{"key":"3112_CR17","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1001\/jama.2024.4840","volume":"331","author":"WY Chen","year":"2024","unstructured":"Chen WY, Ballman KV, Partridge AH, Hahn OM, Briccetti FM, Irvin WJ, et al. Aspirin vs placebo as adjuvant therapy for breast cancer: the Alliance A011502 Randomized Trial. JAMA. 2024;331:1714\u201321.","journal-title":"JAMA"},{"key":"3112_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/bcr3638","volume":"16","author":"LJ Murray","year":"2014","unstructured":"Murray LJ, Cooper JA, Hughes CM, Powe DG, Cardwell CR. Post-diagnostic prescriptions for low-dose aspirin and breast cancer-specific survival: a nested case-control study in a breast cancer cohort from the UK Clinical Practice Research Datalink. Breast Cancer Res. 2014;16:R34.","journal-title":"Breast Cancer Res"},{"key":"3112_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-14-391","volume":"14","author":"MD Holmes","year":"2014","unstructured":"Holmes MD, Olsson H, Pawitan Y, Holm J, Lundholm C, Andersson TM, et al. Aspirin intake and breast cancer survival\u2014a nation-wide study using prospectively recorded data in Sweden. BMC Cancer. 2014;14:391.","journal-title":"BMC Cancer"},{"key":"3112_CR20","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.canep.2017.02.006","volume":"48","author":"\u00daM Menamin","year":"2017","unstructured":"Menamin \u00daM, Cardwell C, Hughes C, Murray L. Low-dose aspirin use and survival in breast cancer patients: a nationwide cohort study. Cancer Epidemiol. 2017;48:158.","journal-title":"Cancer Epidemiol"},{"key":"3112_CR21","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-018-1065-0","volume":"20","author":"G Frisk","year":"2018","unstructured":"Frisk G, Ekberg S, Lidbrink E, Eloranta S, Sund M, Fredriksson I, et al. No association between low-dose aspirin use and breast cancer outcomes overall: a Swedish population-based study. Breast Cancer Res. 2018;20:142.","journal-title":"Breast Cancer Res"},{"key":"3112_CR22","doi-asserted-by":"publisher","first-page":"2067","DOI":"10.1002\/cncr.30004","volume":"122","author":"MC Bradley","year":"2016","unstructured":"Bradley MC, Black A, Freedman AN, Barron TI. Prediagnostic aspirin use and mortality in women with stage I to III breast cancer: a cohort study in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Cancer. 2016;122:2067\u201375.","journal-title":"Cancer"},{"key":"3112_CR23","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-023-01697-2","volume":"25","author":"LL L\u00f6fling","year":"2023","unstructured":"L\u00f6fling LL, St\u00f8er NC, Andreassen BK, Ursin G, Botteri E. Low-dose aspirin, statins, and metformin and survival in patients with breast cancers: a Norwegian population-based cohort study. Breast Cancer Res. 2023;25:101.","journal-title":"Breast Cancer Res"},{"key":"3112_CR24","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.ypmed.2018.09.015","volume":"116","author":"A Bens","year":"2018","unstructured":"Bens A, Friis S, Dehlendorff C, Jensen MB, Ejlertsen B, Kroman N, et al. Low-dose aspirin use and risk of contralateral breast cancer: a Danish nationwide cohort study. Prev Med. 2018;116:186\u201393.","journal-title":"Prev Med"},{"key":"3112_CR25","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1016\/S0140-6736(10)61543-7","volume":"376","author":"PM Rothwell","year":"2010","unstructured":"Rothwell PM, Wilson M, Elwin CE, Norrving B, Algra A, Warlow CP, et al. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. The Lancet. 2010;376:1741\u201350.","journal-title":"The Lancet"},{"key":"3112_CR26","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(10)62110-1","volume":"377","author":"PM Rothwell","year":"2011","unstructured":"Rothwell PM, Fowkes FGR, Belch JF, Ogawa H, Warlow CP, Meade TW. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. The Lancet. 2011;377:31\u201341.","journal-title":"The Lancet"},{"key":"3112_CR27","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1016\/S0140-6736(20)30366-4","volume":"395","author":"J Burn","year":"2020","unstructured":"Burn J, Sheth H, Elliott F, Reed L, Macrae F, Mecklin JP, et al. Cancer prevention with aspirin in hereditary colorectal cancer (Lynch syndrome), 10-year follow-up and registry-based 20-year data in the CAPP2 study: a double-blind, randomised, placebo-controlled trial. Lancet. 2020;395:1855\u201363.","journal-title":"Lancet"},{"key":"3112_CR28","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.cct.2016.10.004","volume":"51","author":"C Coyle","year":"2016","unstructured":"Coyle C, Cafferty FH, Rowley S, MacKenzie M, Berkman L, Gupta S, et al. ADD-ASPIRIN: A phase III, double-blind, placebo controlled, randomised trial assessing the effects of aspirin on disease recurrence and survival after primary therapy in common non-metastatic solid tumours. Contemp Clin Trials. 2016;51:56\u201364.","journal-title":"Contemp Clin Trials"},{"key":"3112_CR29","doi-asserted-by":"publisher","first-page":"449","DOI":"10.2147\/CLEP.S91125","volume":"7","author":"M Schmidt","year":"2015","unstructured":"Schmidt M, Schmidt SAJ, Sandegaard JL, Ehrenstein V, Pedersen L, S\u00f8rensen HT. The Danish National Patient Registry: a review of content, data quality, and research potential. Clin Epidemiol. 2015;7:449\u201390.","journal-title":"Clin Epidemiol"},{"key":"3112_CR30","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1007\/s10654-014-9930-3","volume":"29","author":"M Schmidt","year":"2014","unstructured":"Schmidt M, Pedersen L, S\u00f8rensen HT. The Danish Civil Registration System as a tool in epidemiology. Eur J Epidemiol. 2014;29:541\u20139.","journal-title":"Eur J Epidemiol"},{"key":"3112_CR31","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1080\/02841860802059259","volume":"47","author":"S M\u00f8ller","year":"2008","unstructured":"M\u00f8ller S, Jensen MB, Ejlertsen B, Bjerre KD, Larsen M, Hansen HB, et al. The clinical database and the treatment guidelines of the Danish Breast Cancer Cooperative Group (DBCG); its 30-years experience and future promise. Acta Oncol. 2008;47:506\u201324.","journal-title":"Acta Oncol"},{"key":"3112_CR32","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1080\/02841860802068615","volume":"47","author":"M Blichert-Toft","year":"2008","unstructured":"Blichert-Toft M, Christiansen P, Mouridsen HT. Danish Breast Cancer Cooperative Group \u2013 DBCG: History, organization, and status of scientific achievements at 30-year anniversary. Acta Oncol. 2008;47:497\u2013505.","journal-title":"Acta Oncol"},{"key":"3112_CR33","doi-asserted-by":"publisher","first-page":"51","DOI":"10.2147\/CLEP.S9908","volume":"2","author":"R Erichsen","year":"2010","unstructured":"Erichsen R, Lash TL, Hamilton-Dutoit SJ, Bjerregaard B, Vyberg M, Pedersen L. Existing data sources for clinical epidemiology: the Danish National Pathology Registry and Data Bank. Clin Epidemiol. 2010;2:51\u20136.","journal-title":"Clin Epidemiol"},{"key":"3112_CR34","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1177\/1403494811399958","volume":"39","author":"K Helweg-Larsen","year":"2011","unstructured":"Helweg-Larsen K. The Danish Register of causes of death. Scand J Public Health. 2011;39:26\u20139.","journal-title":"Scand J Public Health"},{"key":"3112_CR35","first-page":"798","volume":"46","author":"A Potteg\u00e5rd","year":"2017","unstructured":"Potteg\u00e5rd A, Schmidt SAJ, Wallach-Kildemoes H, S\u00f8rensen HT, Hallas J, Schmidt M. Data resource profile: the Danish National Prescription Registry. Int J Epidemiol. 2017;46:798\u2013798f.","journal-title":"Int J Epidemiol"},{"key":"3112_CR36","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s10549-018-4846-3","volume":"171","author":"R Langballe","year":"2018","unstructured":"Langballe R, Frederiksen K, Jensen MB, Andersson M, Cronin-Fenton D, Ejlertsen B, et al. Mortality after contralateral breast cancer in Denmark. Breast Cancer Res Treat. 2018;171:489\u201399.","journal-title":"Breast Cancer Res Treat"},{"key":"3112_CR37","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/s10549-020-05847-4","volume":"184","author":"L Saltb\u00e6k","year":"2020","unstructured":"Saltb\u00e6k L, Horsboel TA, Offersen BV, Andersson M, Friberg AS, Skriver SK, et al. Patterns in detection of recurrence among patients treated for breast cancer. Breast Cancer Res Treat. 2020;184:365\u201373.","journal-title":"Breast Cancer Res Treat"},{"key":"3112_CR38","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1161\/CIRCOUTCOMES.110.957951","volume":"4","author":"U Dafni","year":"2011","unstructured":"Dafni U. Landmark analysis at the 25-year landmark point. Circ Cardiovasc Qual Outcomes. 2011;4:363\u201371.","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"3112_CR39","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1111\/tri.13081","volume":"31","author":"A Gleiss","year":"2018","unstructured":"Gleiss A, Oberbauer R, Heinze G. An unjustified benefit: immortal time bias in the analysis of time-dependent events. Transpl Int. 2018;31:125\u201330.","journal-title":"Transpl Int"},{"key":"3112_CR40","doi-asserted-by":"crossref","unstructured":"Sobin LH, Gospodarowicz MK, Wittekind C, editors. TNM Classification of Malignant Tumours. 7th ed. Chichester (UK): Wiley-Blackwell; 2009.","DOI":"10.1002\/9780471420194.tnmc26"},{"key":"3112_CR41","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","volume":"40","author":"ME Charlson","year":"1987","unstructured":"Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373\u201383.","journal-title":"J Chronic Dis"},{"key":"3112_CR42","first-page":"613","volume":"18","author":"ML Kwan","year":"2007","unstructured":"Kwan ML, Habel LA, Slattery ML, Caan B. NSAIDs and breast cancer recurrence in a prospective cohort study. Cancer Causes Control. 2007;18:613\u201320.","journal-title":"Cancer Causes Control"},{"key":"3112_CR43","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1093\/jnci\/djr291","volume":"103","author":"TP Ahern","year":"2011","unstructured":"Ahern TP, Pedersen L, Tarp M, Cronin-Fenton DP, Garne JP, Silliman RA, et al. Statin prescriptions and breast cancer recurrence risk: a Danish nationwide prospective cohort study. J Natl Cancer Inst. 2011;103:1461\u20138.","journal-title":"J Natl Cancer Inst"},{"key":"3112_CR44","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1002\/cncr.23215","volume":"112","author":"R van der Knaap","year":"2008","unstructured":"van der Knaap R, Siemes C, Coebergh JW, van Duijn CM, Hofman A, Stricker BH. Renin-angiotensin system inhibitors, angiotensin I-converting enzyme gene insertion\/deletion polymorphism, and cancer: the Rotterdam Study. Cancer. 2008;112:748\u201357.","journal-title":"Cancer"},{"key":"3112_CR45","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1056\/NEJM200006293422604","volume":"342","author":"S Schulman","year":"2000","unstructured":"Schulman S, Lindmarker P. Incidence of cancer after prophylaxis with warfarin against recurrent venous thromboembolism. Duration of Anticoagulation Trial. N Engl J Med. 2000;342:1953\u20138.","journal-title":"N Engl J Med"},{"key":"3112_CR46","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1158\/1055-9965.EPI-07-0610","volume":"17","author":"PA Newcomb","year":"2008","unstructured":"Newcomb PA, Egan KM, Trentham-Dietz A, Titus-Ernstoff L, Baron JA, Hampton JM, et al. Prediagnostic use of hormone therapy and mortality after breast cancer. Cancer Epidemiol Biomark Prev. 2008;17:864\u201371.","journal-title":"Cancer Epidemiol Biomark Prev"},{"key":"3112_CR47","first-page":"1375","volume":"32","author":"NC Lorona","year":"2021","unstructured":"Lorona NC, Cook LS, Tang MC, Hill DA, Wiggins CL, Li CI. Antihypertensive medications and risks of recurrence and mortality in luminal, triple-negative, and HER2-overexpressing breast cancer. Cancer Causes Control. 2021;32:1375\u201384.","journal-title":"Cancer Causes Control"},{"key":"3112_CR48","doi-asserted-by":"publisher","DOI":"10.1186\/bcr3386","volume":"15","author":"RJ Biggar","year":"2013","unstructured":"Biggar RJ, Andersen EW, Kroman N, Wohlfahrt J, Melbye M. Breast cancer in women using digoxin: tumor characteristics and relapse risk. Breast Cancer Res. 2013;15:R13.","journal-title":"Breast Cancer Res"},{"key":"3112_CR49","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1001\/jama.2022.6147","volume":"327","author":"PJ Goodwin","year":"2022","unstructured":"Goodwin PJ, Chen BE, Gelmon KA, Whelan TJ, Ennis M, Lemieux J, et al. Effect of metformin vs placebo on invasive disease-free survival in patients with breast cancer: the MA.32 Randomized Clinical Trial. JAMA. 2022;327:1963\u201373.","journal-title":"JAMA"},{"key":"3112_CR50","doi-asserted-by":"publisher","first-page":"3018","DOI":"10.2337\/dc12-2535","volume":"36","author":"IC Lega","year":"2013","unstructured":"Lega IC, Austin PC, Gruneir A, Goodwin PJ, Rochon PA, Lipscombe LL. Association between metformin therapy and mortality after breast cancer: a population-based study. Diabetes Care. 2013;36:3018\u201326.","journal-title":"Diabetes Care"},{"key":"3112_CR51","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1634\/theoncologist.2015-0096","volume":"20","author":"H Xu","year":"2015","unstructured":"Xu H, Chen K, Jia X, Tian Y, Dai Y, Li D, et al. Metformin use is associated with better survival of breast cancer patients with diabetes: a meta-analysis. Oncologist. 2015;20:1236\u201344.","journal-title":"Oncologist"},{"key":"3112_CR52","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1080\/02841860802056594","volume":"47","author":"P Christiansen","year":"2008","unstructured":"Christiansen P, Al-Suliman N, Bjerre K, M\u00f8ller S. Recurrence pattern and prognosis in low-risk breast cancer patients-data from the DBCG 89-A programme. Acta Oncol. 2008;47:691\u2013703.","journal-title":"Acta Oncol"},{"key":"3112_CR53","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.2147\/CLEP.S269962","volume":"12","author":"RN Pedersen","year":"2020","unstructured":"Pedersen RN, \u00d6zt\u00fcrk B, Mellemkj\u00e6r L, Friis S, Tramm T, N\u00f8rgaard M, et al. Validation of an algorithm to ascertain late breast cancer recurrence using danish medical registries. Clin Epidemiol. 2020;12:1083.","journal-title":"Clin Epidemiol"},{"key":"3112_CR54","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1093\/oncolo\/oyad186","volume":"29","author":"A Baker","year":"2023","unstructured":"Baker A, Kartsonaki C. Aspirin use and survival among patients with breast cancer: a systematic review and meta-analysis. The Oncologist. 2023;29:e1\u201314.","journal-title":"The Oncologist"},{"key":"3112_CR55","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1038\/bjc.2014.264","volume":"111","author":"DM Fraser","year":"2014","unstructured":"Fraser DM, Sullivan FM, Thompson AM, McCowan C. Aspirin use and survival after the diagnosis of breast cancer: a population-based cohort study. Br J Cancer. 2014;111:623\u20137.","journal-title":"Br J Cancer"},{"key":"3112_CR56","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1007\/s10549-006-9277-x","volume":"101","author":"CK Blair","year":"2007","unstructured":"Blair CK, Sweeney C, Anderson KE, Folsom AR. NSAID use and survival after breast cancer diagnosis in post-menopausal women. Breast Cancer Res Treat. 2007;101:191\u20137.","journal-title":"Breast Cancer Res Treat"},{"key":"3112_CR57","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1080\/0284186X.2017.1327720","volume":"56","author":"DP Cronin-Fenton","year":"2017","unstructured":"Cronin-Fenton DP, Kj\u00e6rsgaard A, Ahern TP, Mele M, Ewertz M, Hamilton-Dutoit S, et al. Validity of Danish Breast Cancer Group (DBCG) registry data used in the predictors of breast cancer recurrence (ProBeCaRe) premenopausal breast cancer cohort study. Acta Oncol. 2017;56:1155\u201360.","journal-title":"Acta Oncol"},{"key":"3112_CR58","doi-asserted-by":"publisher","first-page":"569","DOI":"10.2147\/CLEP.S311450","volume":"13","author":"N Gaster","year":"2021","unstructured":"Gaster N, Hallas J, Potteg\u00e5rd A, Friis S, Schmidt M. The validity of danish prescription data to measure use of aspirin and other non-steroidal anti-inflammatory drugs and quantification of bias due to non-prescription drug use. Clin Epidemiol. 2021;13:569\u201379.","journal-title":"Clin Epidemiol"},{"key":"3112_CR59","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1080\/17425255.2024.2386368","volume":"20","author":"JL Visagie","year":"2024","unstructured":"Visagie JL, Aruwajoye GS, van der Sluis R. Pharmacokinetics of aspirin: evaluating shortcomings in the literature. Expert Opin Drug Metab Toxicol. 2024;20:727\u201340.","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"3112_CR60","first-page":"110","volume":"4","author":"SL Navarro","year":"2011","unstructured":"Navarro SL, Saracino MR, Makar KW, Thomas SS, Li L, Zheng Y, et al. Determinants of Aspirin metabolism in healthy men and women: effects of dietary inducers of UDP-glucuronosyltransferases. J Nutr Nutr. 2011;4:110\u20138.","journal-title":"J Nutr Nutr"},{"key":"3112_CR61","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1016\/S0169-409X(02)00076-5","volume":"54","author":"HG Xie","year":"2002","unstructured":"Xie HG, Prasad HC, Kim RB, Stein CM. CYP2C9 allelic variants: ethnic distribution and functional significance. Adv Drug Deliv Rev. 2002;54:1257\u201370.","journal-title":"Adv Drug Deliv Rev"},{"key":"3112_CR62","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1159\/000365952","volume":"9","author":"MAN Sendur","year":"2014","unstructured":"Sendur MAN, Aksoy S, Ozdemir NY, Zengin N, Altundag K. Impact of acetylsalicylic acid on the clinicopathological characteristics and prognosis of patients with invasive breast cancer. Breast Care. 2014;9:261\u20136.","journal-title":"Breast Care"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41416-025-03112-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-025-03112-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-025-03112-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T11:03:00Z","timestamp":1758279780000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-025-03112-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,22]]},"references-count":62,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,10,5]]}},"alternative-id":["3112"],"URL":"https:\/\/doi.org\/10.1038\/s41416-025-03112-3","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,22]]},"assertion":[{"value":"16 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"LM reports having an immediate family member who is employed at Novo Nordisk and an immediate family member who owns stocks in Novo Nordisk. BE reports an Advisory Role: Eli Lilly; Research funding: Institutional grants from AstraZeneca, Daiichi Sankyo, Eli Lilly, Gilead, Novartis, Pfizer, and Seagen; and Travel, Accommodations, Expenses: Daiichi Sankyo, MSD, and Pfizer, all outside the submitted work. ES is a board member of the Danish Society of Pharmacoepidemiology, which is unrelated to the current manuscript. The Department of Clinical Epidemiology, Aarhus University, receives funding for other studies from the European Medicines Agency and from companies in the form of research grants, unrelated to the current study. All other authors have no disclosures.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was based entirely on data hosted at the secure servers maintained by the Danish Health Data Authority. In accordance with Danish law, no ethics approval was required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}